raw materials success commercialisation at scale

[E-BOOK] Raw Materials at Scale: Success Factors for Commercial Cell and Gene Therapy Manufacturing

The case for achieving ancillary/raw material consistency and flexibility of deliverability for manufacturing partnership at scale
The nascent field of cell and gene therapy is poised to experience growing pains that other, later-stage therapeutic industries have already come to know.

This eBook, created in partnership with Bio-Techne, explores the anticipated challenges to the industry's growing commercialisable pipeline, as well as the way in which those challenges may be considered unique to advanced therapy medicinal products (ATMPs).
“You identify the nuances of any given problem and then you find the most elegant solution. Everything comes down to a robust and consistent process and matching the design mantra via our customer requirements is what moves the needle." - Sean Kevlahan, Ph.D, Senior Director Cell & Gene Therapy, Bio-Techne
  • Key insights from industry experts
  • How consistency, flexibility of deliverables and partnerships are key considerations for manufacturing at scale
  • An exclusive Q&A with bio-techne’s Senior Director of Cell & Gene Therapy, Sean Kevlahan, Ph.D.

Bio-Techne is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Bio-Techne's product portfolio, representing the biomedical research brands of R&D Systems, Novus Biologicals, Tocris, ProteinSimple and ACD, assists scientific investigations into biological processes and the nature and progress of specific diseases. Additionally, Bio-Techne has announced an initiative to advance cell and gene therapy research and ex vivo cell processing as part of its mission of providing "Pioneering Cell and Gene Therapy Solutions from Discovery to the Clinic."